Jiao et al. also demonstrated that exosomes with albumin and vascular endothelial growth factor (VEGF) may be more accurate and specific biomarkers for assessing liver regeneration and prognosis in patients with acute-on-chronic liver failure (ACLF), whereas exosomes with CD63 and albumin may be early warning markers for patients with ACLF (25). The gene discussed is VEGFA; the disease is acute-on-chronic liver failure.